阿尔茨海默病的治疗：当前治疗方法的效果如何？
Therapy for Alzheimer's Disease: How Effective are Current Treatments?
机构信息
Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
出版信息
Ther Adv Neurol Disord. 2009 May;2(3):163-80. doi: 10.1177/1756285609102724.
Abstract
Available symptomatic therapies for the treatment of Alzheimer's disease (AD) have been based on known neurotransmitter dysfunctions associated with the illness. The second-generation cholinesterase inhibitors and the N-methyl D-aspartate receptor antagonist memantine have been widely prescribed and studied. Meta-analyses of these therapies were reviewed, focusing on effectiveness and tolerability. Although many of the meta-analyses demonstrate statistically significant improvements, some question if these benefits are sufficient to justify their current widespread and protracted use. This has spurred the development of new disease-modifying therapies that aim to have a greater impact on this debilitating illness.
摘要
目前用于治疗阿尔茨海默病（AD）的对症疗法是基于已知的与该病相关的神经递质功能障碍。第二代胆碱酯酶抑制剂和 N-甲基-D-天冬氨酸受体拮抗剂美金刚已被广泛应用和研究。对这些疗法的荟萃分析进行了综述，重点关注有效性和耐受性。尽管许多荟萃分析显示出统计学上的显著改善，但一些人质疑这些益处是否足以证明它们目前广泛而长期使用的合理性。这促使开发了新的疾病修饰疗法，旨在对这种使人衰弱的疾病产生更大的影响。
相似文献
1
Therapy for Alzheimer's Disease: How Effective are Current Treatments?阿尔茨海默病的治疗：当前治疗方法的效果如何？
Ther Adv Neurol Disord. 2009 May;2(3):163-80. doi: 10.1177/1756285609102724.
2
Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.银杏叶提取物（EGb761）、胆碱酯酶抑制剂和盐酸美金刚治疗轻中度阿尔茨海默病：一项网络荟萃分析。
Drugs Aging. 2019 May;36(5):435-452. doi: 10.1007/s40266-019-00648-x.
3
Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.胆碱酯酶抑制剂治疗阿尔茨海默病：耐受性与药理学比较
Drug Saf. 1998 Dec;19(6):465-80. doi: 10.2165/00002018-199819060-00004.
4
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.多奈哌齐、加兰他敏、利伐斯的明和美金刚治疗阿尔茨海默病的有效性和成本效果（技术评估第 111 号回顾）：系统评价和经济模型。
Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.
5
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.多奈哌齐、卡巴拉汀、加兰他敏和美金刚用于治疗阿尔茨海默病的临床疗效及成本效益
Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. doi: 10.3310/hta10010.
6
[Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].[抗痴呆药物（抗阿尔茨海默病药物）]
Brain Nerve. 2023 May;75(5):464-469. doi: 10.11477/mf.1416202360.
7
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.当前特定治疗方法对阿尔茨海默病患者行为和心理症状的影响差异：一项 12 个月、随机、开放标签试验。
J Alzheimers Dis. 2014;39(3):477-85. doi: 10.3233/JAD-131190.
8
Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease.治疗、控制和管理阿尔茨海默病药物（如美金刚、多奈哌齐、利斯的明和阿杜卡玛单抗）的挑战与方法。
Recent Pat Biotechnol. 2022;16(2):102-121. doi: 10.2174/1872208316666220302115901.
9
Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease.他克林类杂合体作为阿尔茨海默病治疗选择的最新进展。
Mini Rev Med Chem. 2023;23(7):869-880. doi: 10.2174/1389557523666221201145141.
10
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.多奈哌齐、加兰他敏、卡巴拉汀和美金刚治疗阿尔茨海默病的疗效与安全性：一项系统评价和荟萃分析。
J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690.
引用本文的文献
1
Risk of Antipsychotic Initiation Among Older Dementia Patients Initiating Cholinesterase Inhibitors.开始使用胆碱酯酶抑制剂的老年痴呆患者中开始使用抗精神病药物的风险。
Drug Healthc Patient Saf. 2025 Mar 20;17:75-85. doi: 10.2147/DHPS.S506523. eCollection 2025.
2
Feasibility of Identifying Factors Related to Alzheimer's Disease and Related Dementia in Real-World Data.在真实世界数据中识别与阿尔茨海默病及相关痴呆症相关因素的可行性
medRxiv. 2024 Feb 13:2024.02.10.24302621. doi: 10.1101/2024.02.10.24302621.
3
Neuroprotective effect of ranolazine improves behavioral discrepancies in a rat model of scopolamine-induced dementia.雷诺嗪的神经保护作用改善了东莨菪碱诱导的痴呆大鼠模型中的行为差异。
Front Neurosci. 2024 Jan 12;17:1267675. doi: 10.3389/fnins.2023.1267675. eCollection 2023.
4
Neuroprotective Potential of Seed Extracts: Review of In Vitro and In Vivo Studies.种子提取物的神经保护潜力：体外和体内研究综述。
Nutrients. 2023 May 27;15(11):2502. doi: 10.3390/nu15112502.
5
Artificial intelligence assisted identification of potential tau aggregation inhibitors: ligand- and structure-based virtual screening, in silico ADME, and molecular dynamics study.人工智能辅助鉴定潜在的 tau 聚集抑制剂：基于配体和结构的虚拟筛选、计算机 ADME 和分子动力学研究。
Mol Divers. 2024 Aug;28(4):2013-2031. doi: 10.1007/s11030-023-10645-3. Epub 2023 Apr 6.
6
Potential Anti-Amnesic Activity of a Novel Multimodal Derivative of Salicylamide, JJGW08, in Mice.新型水杨酰胺多模态衍生物JJGW08对小鼠的潜在抗遗忘活性
Pharmaceuticals (Basel). 2023 Mar 6;16(3):399. doi: 10.3390/ph16030399.
7
The Monkey Head Mushroom and Memory Enhancement in Alzheimer's Disease.猴头菇与阿尔茨海默病的记忆力增强。
Cells. 2022 Jul 24;11(15):2284. doi: 10.3390/cells11152284.
8
Therapeutic Potential of Human Stem Cell Implantation in Alzheimer's Disease.人干细胞移植治疗阿尔茨海默病的潜力。
Int J Mol Sci. 2021 Sep 21;22(18):10151. doi: 10.3390/ijms221810151.
9
Role of Withaferin A and Its Derivatives in the Management of Alzheimer's Disease: Recent Trends and Future Perspectives.铁皮石斛素 A 及其衍生物在阿尔茨海默病治疗中的作用：最新趋势和未来展望。
Molecules. 2021 Jun 17;26(12):3696. doi: 10.3390/molecules26123696.
10
Bay Leaf ( L.) Incense Improved Scopolamine-Induced Amnesic Rats by Restoring Cholinergic Dysfunction and Brain Antioxidant Status.月桂叶（L.）香薰通过恢复胆碱能功能障碍和脑抗氧化状态改善东莨菪碱诱导的记忆缺失大鼠。
Antioxidants (Basel). 2021 Feb 8;10(2):259. doi: 10.3390/antiox10020259.
本文引用的文献
1
Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.口服降糖药物试验中的心血管结局：一项系统评价。
Arch Intern Med. 2008 Oct 27;168(19):2070-80. doi: 10.1001/archinte.168.19.2070.
2
Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study.中年及老年糖尿病与痴呆症风险的关系：一项基于人群的双胞胎研究。
Diabetes. 2009 Jan;58(1):71-7. doi: 10.2337/db08-0586. Epub 2008 Oct 24.
3
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.2 型糖尿病患者胰腺中的β淀粉样蛋白和过度磷酸化的 tau 沉积。
Neurobiol Aging. 2010 Sep;31(9):1503-15. doi: 10.1016/j.neurobiolaging.2008.08.019. Epub 2008 Oct 23.
4
Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease.锂降低糖原合成酶激酶3β（Gsk3b）的信使核糖核酸（mRNA）水平：对阿尔茨海默病的影响。
Eur Arch Psychiatry Clin Neurosci. 2009 Feb;259(1):16-22. doi: 10.1007/s00406-008-0828-5. Epub 2008 Oct 17.
5
Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study.无论亲脂性如何，他汀类药物都与阿尔茨海默病风险降低相关。鹿特丹研究。
J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):13-7. doi: 10.1136/jnnp.2008.150433. Epub 2008 Oct 17.
6
Association of GSK3B with Alzheimer disease and frontotemporal dementia.糖原合成酶激酶3β（GSK3B）与阿尔茨海默病和额颞叶痴呆的关联。
Arch Neurol. 2008 Oct;65(10):1368-74. doi: 10.1001/archneur.65.10.1368.
7
Does analysis using "last observation carried forward" introduce bias in dementia research?使用“末次观察值结转”进行分析是否会在痴呆症研究中引入偏差？
CMAJ. 2008 Oct 7;179(8):751-3. doi: 10.1503/cmaj.080820.
8
Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.抗氧化剂和吡格列酮（一种过氧化物酶体增殖物激活受体γ激动剂）可使老年阿尔茨海默病转基因小鼠的脑血管功能完全恢复。
J Neurosci. 2008 Sep 10;28(37):9287-96. doi: 10.1523/JNEUROSCI.3348-08.2008.
9
Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease.外周β淀粉样蛋白亚型作为阿尔茨海默病的风险生物标志物。
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14052-7. doi: 10.1073/pnas.0805902105. Epub 2008 Sep 8.
10
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.在阿尔茨海默病中使用γ-分泌酶抑制剂针对β淀粉样蛋白生成的2期安全性试验。
Arch Neurol. 2008 Aug;65(8):1031-8. doi: 10.1001/archneur.65.8.1031.
Zotero 插件